Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma

Table 2 Direct-acting antiviral agents-based antiviral treatment in hepatitis C virus-infected patients with low-grade non-Hodgkin lymphomas

	Year	No. of patients	Diagnosis	Genotypes	Cryoglobulinemia	Antiviral treatment	Virologic response	NHL response
Rossotti et al[58]	2015	1	SMZL	1b	Yes (type II MC)	FDV + DLV + RBV (16 w)	SVR	PR
Sultanik et al[59]	2015	1	MALT MZL (breast, humeral shaft, cervical lymph node)	3a	Yes (type II MC)	SOF + RBV (4 w), then SOF + DCV (12 w)	SVR	CR
								(ongoing at 6 m)
Carrier et al[60]	2015	3	1 Leukemic MZL	4	3 (type II MC)	SOF - SIM	3 SVR	PR
			1 MALT MZL (kidney)	1b		SOF - SIM + 4 Rtx		CR
			1 SMZL	1b		SOF - DCV		CR
Lim et al[61]	2015	1	SMZL	2	No	SOF + RBV (12 w)	SVR	CR
								(ongoing at 17 m)
Arcaini et al[62]	2015	20	9 SMZL	1 (n = 13)	10 (50%)	various	19 SVR	4 CR, 2 PR, 2 SD 1 PD
			1 NMZL (Nodal)	2 (n = 3)		SOF-based regimens		1 CR
			5 MALT MZL	3 (n = 3)				2 CR, 1 PR, 2 PD
			2 Leukemic MZL	4 (n = 1)		(+ 4 Rtx in 1 pts)		1 CR, 1 PR
			2 CLL					2 SD
			1 LPL					1 SD

DAA: Direct-acting antiviral agents; SMZL: Splenic marginal zone lymphoma; NMZL: Nodal marginal zone lymphoma; phocytes; MZL: Marginal zone lymphoma; LPL: Lymphoplasmacytic lymphoma; MC: Mixed cryoglobulinemia; FDV: Faldaprevir; DLV: Deleobuvir; RBV: Ribavirine; SOF: Sofosbuvir; DCV: Daclatasvir; SVR: Sustained virologic response; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; Rtx: Rituximab.